Tutorial: Introduction to Markov modelling
|
|
- Shannon Blankenship
- 5 years ago
- Views:
Transcription
1 Tutorial: Introduction to Markov modelling Mats O Karlsson Pharmacometrics Research Group Department of Pharmaceutical Biosciences Uppsala University Sweden
2 Coin toss Assume a coin has been tossed n times P tails =/2 (if perfect coin) Q: What is the probability of tails at the next toss P n+ ( tails ) = P tails Outcome is dependent on P tails only and not dependent on outome of previous tosses 2
3 Coin toss Assume a coin has been tossed n times P tails =/2 (perfect coin) Q: What is the total number of tails (S n+ ( tails )) after the next toss P n+ (S n+ ( tails )<S n ( tails )) = P n+ (S n+ ( tails )=S n ( tails )) = P tails P n+ (S n+ ( tails )=S n ( tails )+) = P tails P n+ (S n+ ( tails )>S n ( tails )+2) = Outcome is dependent on P tails and outomes of previous tosses S n ( tails ) contains all necessary information about prior history 3
4 Definition Markov property The Markov property, proposed by A.A. Markov ( ), asserts that the distribution of future outcomes depend only on the current state and not on the whole history 4
5 Modeling of sleep/wake state Example: Nighttime observations of awake or sleep every 5th minute in an insomniac patient Asleep (=) Awake (=) Time (h) 5
6 Logistic model NMTRAN $PROB Logistic model for sleep and awake $DATA data $INPUT DV $PRED P = THETA() IF(DV.EQ.) Y=P IF(DV.EQ.) Y=-P $THETA (,.5,) ; PROBABILITY OF BEING ASLEEP $ESTIM LIKE 6
7 P Two-state Markov model (Awake) P P (Asleep) P P = P P = - P 7
8 Markov model NMTRAN code $PROB Transition probabilities between sleep and awake $DATA data $INPUT DV PDV ;PDV=Previous DV ;PDV = Value of immediately preceding observation $PRED P = THETA() P = THETA(2) IF(PDV.EQ..AND.DV.EQ.) Y=P IF(PDV.EQ..AND.DV.EQ.) Y=-P IF(PDV.EQ..AND.DV.EQ.) Y=P IF(PDV.EQ..AND.DV.EQ.) Y=-P $THETA (,.,) ; PROB AWAKE GIVEN ASLEEP $THETA (,.,) ; PROB ASLEEP GIVEN AWAKE $ESTIM LIKE 8
9 Same model MLXTRAN code DESCRIPTION: Categorical data model with Markovian dependence, Binomial distribution INPUT: parameter = {p, p} OBSERVATION: Y = { } type = categorical categories = {,} dependence = Markov P(Y= Yp=) = p P(Y= Yp=) = p 9
10 Results Logistic model P =.43.5 OFV 32.7 Markov model P =..4 OFV 72.4 P =.4.5
11 P Two-state Markov model (Awake) P P (Asleep) P Transition Matrix PDV= PDV= DV=.89.4 DV=..86
12 Simulations Original data Time (h) Simulation from logistic model Time (h) Simulation from Markov model Time (h) 2
13 P Discrete-time Markov model (Awake) P P (Asleep) P Continuous-time Markov model (Awake) K K (Asleep) 3
14 Continuous-time Markov model $PROB Continuous-time two-state Markov model for awake/asleep $DATA data $INPUT DV PDV DELTAT $PRED K = THETA() K = THETA(2) P = (EXP(-(K+K)*DELTAT)*K+K)/(K+K) P = (EXP(-(K+K)*DELTAT)*K+K)/(K+K) IF(PDV.EQ..AND.DV.EQ.) Y=P IF(PDV.EQ..AND.DV.EQ.) Y=-P IF(PDV.EQ..AND.DV.EQ.) Y=P IF(PDV.EQ..AND.DV.EQ.) Y=-P $THETA (,) ; K ASLEEP GIVEN AWAKE $THETA (,) ; K AWAKE GIVEN ASLEEP $ESTIM LIKE 4
15 Continuous time Markov model - differential eqn parametrization $PROB Transition probability between awake and asleep $DATA data $INPUT DV TIME AMT CMT EVID ; Complex data set to initiate and empty compartments ; to reset compartment amounts after each observation $MODEL COMP=PRWAKE COMP=PRSLP $PK K = THETA() K = THETA(2) $DES DADT() = - K*A() + K*A(2) ;Represents Probability of - awake DADT(2) = K*A() K*A(2) ;Represents Probability of - asleep $ERROR IF(DV.EQ.) Y = A() IF(DV.EQ.) Y = A(2) $THETA (,) ; K ASLEEP GIVEN AWAKE $THETA (,) ; K AWAKE GIVEN ASLEEP $ESTIM LIKE 5
16 Data set for differential eqn solution to Markov model $PROB Two-state Markov model ; Entire system updated after each observation $DATA data $INPUT DV TIME AMT CMT EVID ;. ;awake at start - initialization ;. ;obs awake at T= ;. 4 ;set probabilities to P(awake)= ; 2. ;obs asleep at T=2 ; ;set probabilities to P(asleep)= 6
17 Data set for differential eqn solution to Markov model $PROB Two-state Markov model ;Data set structure with updating compartment by compartment ;May be needed when not entire system is to be updated (e.g. PKPD model) $DATA data $INPUT DV TIME AMT CMT EVID ;. ;awake at start - initialization ;. ;awake at T= ;. - 2 ; empty compartment ; ; empty compartment 2 ;. ; reinitialize comp to ;. 2 2 ; restart comp 2 with ; 2. ;asleep at T=2 ;. 2-2 ; empty compartment ; ; empty compartment 2 ;. 2 2 ; reinitialize comp 2 to ;. 2 2 ; restart comp with 7
18 Probability Probabilities following an awake observation at time= No additional observations made p = K K + K + K K + K e K+K t P P Time (h) 8
19 Probability Probabilities following an awake observation at time= Additional observations made at h (awake) and 2 h (asleep) Time (h) P (awake) P (asleep) 9
20 Probability Probability Probability Probability Introducing a treatment effect Without treatment With treatment P (awake) P (asleep) Time (h) Time (h) Promote falling asleep K K K+K Inhibit waking up K K K+K (Awake) K K (Asleep) Time (h) Time (h) Both effects K K K+K 2
21 Clues about mechanism in data Mechanism Total sleep time Average time of sleep episodes Average time of awake episodes # of arousals # of times falling asleep Total # of State transitions Promote falling asleep Inhibit waking up Both effects K+K 2
22 Repeated time to event analysis an alternative to Markov model Assume transitions as events Assume no unobserved transitions Separate (constant) hazards for waking up and falling asleep Asleep (=) I I I I I I Awake (=) X X X X X Time (h) X X event during awake period (falling asleep) censoring during awake period I event during sleeping period (arousal) 22
23 RTTE model NMTRAN $PROB Repeated Time To Event data - constant hazard $INPUT ID DV TYPE DVID $DATA data $PRED IF(TYPE.EQ.) HAZ= THETA() ;hazard for waking up IF(TYPE.EQ.) HAZ= THETA(2) ;hazard for falling asleep CUMHAZ = HAZ*DV ;cumulative hazard SUR = EXP(-CUMHAZ) ;survival probability IF(DVID.EQ.) Y = HAZ*SUR ;event IF(DVID.EQ.2) Y = SUR ;censoring $THETA (,.46) ; HAZ_WK (/5min) $THETA (,.9) ; HAZ_SL (/5min) $ESTIM LIKE 23
24 No of abstracts Markov PAGE Markov models Hidden Markov models
25 Bergstrand Bizzotto Pharmacometric Markov models GI movement Sleep Non-ordered categorical Non-ordered categorical Compartmental chain 29 CPT st order + stagetime 28 PAGE Girard Adherence 3-state categorical Discrete-time 998 Stat Med Henin Hand-and-foot syndrome Ordered categorical st order 28 CPT Ito Dizziness Ordered categorical st order 28 CPT Karlsson Sleep Non-ordered categorical st order + stagetime 2 CPT Karlsson Sedation Ordered categorical st order +stagetime 22 Kjellsson Sleep Non-ordered categorical Measurement and kinetics of in vivo drug effects st order + stagetime 26 PAGE Lacroix ACR2 Binary + dropout st order 29 CPT Maas Migraine Ordered categorical Hidden Markov 26 Cephalalgia Plan None Count st order 29 JPKPD Snoeck Seizures Count st order 27 PAGE Troconiz Seizures Count st order 27 PAGE Zandvliet Follicules Multinomial count Compartmental chain 28 PAGE Zingmark Side-effect Ordered categorical st order 25 JPKPD 25
26 Markov model for responder, nonresponder and dropout Ex, ACR2 score in Rheumatoid Arthritis Pr of remaining non-responder Non- Responder Pr of becoming responder Pr of becoming non-responder Responder Pr of remaining responder Pr 2 of dropping out Pr 2 of dropping out Absorbing state cannot leave the state Absorbing chain absorbing state can be reached from all other states 2 Dropped out Lacroix et al., Clin Pharmacol Ther, 29 26
27 NMTRAN code Responder, non-responder and dropout $PRED ;----transition from being a responder to non- responder--- LGT=LOG(THETA()/(-THETA())) + ETA() P=EXP(LGT)/(+EXP(LGT)) ;----transition from responder to dropout--- LGT2=LOG(THETA(2)/(-THETA(2))) P2=EXP(LGT2)/(+EXP(LGT2)) ;-- transitions from being a non-responder to a responder--- LGT=LOG(THETA(3)/(-THETA(3))) + ETA(2) P=EXP(LGT)/(+EXP(LGT)) ; transition's probabilities IF (PREV.EQ..AND.DV.EQ.) Y=P IF (PREV.EQ..AND.DV.EQ.2) Y=P2*(-P) IF (PREV.EQ..AND.DV.EQ.) Y=-P-P2*(-P) IF (PREV.EQ..AND.DV.EQ.) Y=P IF (PREV.EQ..AND.DV.EQ.2) Y=P2*(-P) IF (PREV.EQ..AND.DV.EQ.) Y=-P-P2*(-P) $EST METH= LAPLACE LIKE ;---transition from non-responder to dropout--- LGT2=LOG(THETA(2)/(-THETA(2))) P2=EXP(LGT2)/(+EXP(LGT2)) 27
28 Diagnostics ACR2 model - proportion responders Lacroix et al., Clin Pharmacol Ther, 29 28
29 Diagnostics ACR2 model - transitions 29
30 Concentration (nmol/l) Score Concentration (nmol/l) Score Concentration (nmol/l) Score Concentration (nmol/l) Score Spontaneous reporting of a side-effect Concentration Score Concentration Score Time (h) Concentration Score Time (h) Concentration Score Time (h) Time (h) Zingmark et al., JPKPD 25 3
31 Side-effect score Alternative assumptions regarding nature of transitions Time (h) For RTT(C)E implementation see Plan et al., CP&T 2 3
32 Parameterization of the model D b b pre l D b pre l D b b pre l D b pre l D b b pre l D b pre l S S S S S S Ce TC C EC Ce e E D tol pre i ) ( 5 5,,2 max lx lx x e e PC p S= = -PC S p S= = PC S -PC S=2 p S=2 = PC S=2
33 Spontaneous reporting of a side-effect - model simulations Proportional odds model Markov model Number of transitions min 3 min 6 min min 3 min 6 min Observed data (249; 335) (2; 33) (62; 82) (9; 4) (8; 5) (8; 5) (33; 223) (64; 95) (39; 59) (2; 29) (2; 29) (2; 29) The results shown are the average and ( th and 9 th percentiles) from simulated datasets The performance of the proportional odds model, but not the Markov model, is dependent on the choice of observation frequency 33
34 Sleep scoring non-ordered categorical data 2 Awake REM Stage - Stage 2-2 Stage 3-3 Stage Time (h) (Karlsson et al., CPT 2) 34
35 Choice of transitions to model To reduce the number of transitions to model, three criteria were defined to identify the transitions of interest representing: (i) >% of all observations in a stage, (ii) >% of all transitions from a stage (iii) >% of all transitions to a stage A transition was modeled, if at least one of these criteria was fulfilled (Kjellsson et al., PAGE 27) 35
36 Overall sleep pattern (Karlsson et al., CPT 2) 36
37 Probability of falling asleep Probability of falling asleep Probability of falling asleep Transition dependences Time of night Time in stage Concentration 37
38 What previous info to condition on? First-order Markov models often sufficient Sometimes biological processes dictate use of higher-order Markov elements 2nd (3rd etc) order elements Time since entering present stage (stagetime) Prior stage(s) 38
39 How to start a Markov chain? Sometimes obvious Sleep-wake data that starts at bed-time Responder status for ACR2 Sometimes screening data provide information about initial state Transform first observation(s) to a covariate for starting the chain 39
40 Sedation score Sedation scores following stroke Time (h) Karlsson et al., in Measurement and Kinetics of in vivo drug effects, 22 4
41 Alternative assumptions regarding nature of transitions Many transitions to model No assumption about intermediate transition states Fewer transitions to model Assumption about intermediate transition states 4
42 Sedation score Sedation score Sedation score Individual time courses of sedation Observations Time (h) Markov model simulations Time (h) Ordered categorical model simulations Time (h) 42
43 Model for GI transit A K FA K AF F Stomach F = proximal stomach A = distal stomach K AS K SI K SI K SI Small intestine SI:-4 transit SI: SI:2 SI:3 SI:4 Colon AC = Ascending colon TC = Transverse colon DC = Descending colon DC K TC TC K AC AC K SI K DC SCR Sigmoid colon / Rectum Bergstrand et al., CPT 29 43
44 Probability Probability GI position Proximal stomach Distal stomach Small intestine Colon Time after dose (h) Time after dose (h) 44
45 Count data - daily seizure scores in epileptic patients Time (days) Markov model; Troconiz et al., JPKPD 36:46-77 (29) Hidden Markov model; Delattre et al., JPKPD 39:263-7 (22) 45
46 Consequences of ignoring Markov properties - estimation Information content in data overestimated SEs underestimated Hypothesis tests inappropriate Interindividual variability overestimated Potential structural model misspecification No info on time-course of dependence 46
47 Consequences of ignoring Markov properties simulation & design Duration of state periods too low Inflated number of transitions Inflated number of extreme value occurrencies E.g. distribution of maximum severity score in population Individualisation strategy suboptimal Value of more frequent observations overrated Positioning of observation times Optimal design results inappropriate* *Optimal design w/ Markov models; Nyberg & Hooker PAGE 2 47
48 Markov model or not? Start with Markov Frequent observations Many consequtive same-state observations Many levels of response Non-ordered categorical data Start without Markov and diagnose Check number of transitions Check average duration of same-state periods 48
49 Thank you! 49
PKPD. Workshop. Warfarin Data. What does this mean? Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand
1 PKPD Workshop Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand 2 Holford NHG, Sheiner LB. Kinetics of pharmacologic response. Pharmacol. Ther. 1982;16:143-166
More informationPKPD. Workshop. Warfarin Data. What does this mean? Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand
1 PKPD Workshop Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand Holford NHG, Sheiner LB. Kinetics of pharmacologic response. Pharmacol. Ther. 198;16:143-166 Pharmacokinetics
More informationOutline. What is a VPC? Model Evaluation. What is a Visual Predictive Check? What choices are there in presentation? What can it help to show?
1 Model Evaluation Visual Predictive Checks www.page-meeting.org/?abstract=1434 PAGE 2008 Marseille Nick Holford University of Auckland Mats Karlsson University of Uppsala 2 Outline What is a Visual Predictive
More informationRTTE modelling of opioid consumption in postoperative pain
RTTE modelling of opioid consumption in postoperative pain Rasmus Vestergaard Juul Department of Drug Design and Pharmacology PAGE 2016 RV Juul - PAGE 2016 10 Jun 2016 2 Postoperative pain A major healthcare
More informationCLADRIBINE TABLETS DOSING RULES
CLADRIBINE TABLETS DOSING RULES Simulation analysis of absolute lymphocytes counts (ALC) and relapse rate (RR) following cladribine treatment rules in subjects with relapsing-remitting multiple sclerosis
More informationApplication of Item Response Theory to ADAS-cog Scores Modeling in Alzheimer s Disease
Application of Item Response Theory to ADAS-cog Scores Modeling in Alzheimer s Disease Sebastian Ueckert 1, Elodie L. Plan 2, Kaori Ito 3, Mats O. Karlsson 1, Brian W. Corrigan 3, Andrew C. Hooker 1 1.
More informationModeling and Simulation to Support Development and Approval of Complex Products
Modeling and Simulation to Support Development and Approval of Complex Products Mathangi Gopalakrishnan, MS, PhD Research Assistant Professor Center for Translational Medicine, School of Pharmacy, UMB
More informationJoão A. Abrantes 1, Alexander Solms 2, Dirk Garmann 3, Elisabet I. Nielsen 1, Siv Jönsson 1, Mats O. Karlsson 1
Integrated modelling of factor VIII activity kinetics, occurrence of bleeds and individual characteristics in haemophilia A patients using a full random effects modelling (FREM) approach João A. Abrantes
More informationInsulin Secretion and Hepatic Extraction during Euglycemic Clamp Study: Modelling of Insulin and C-peptide data
Insulin Secretion and Hepatic Extraction during Euglycemic Clamp Study: Modelling of Insulin and C-peptide data Chantaratsamon Dansirikul Mats O Karlsson Division of Pharmacokinetics and Drug Therapy Department
More informationRada Savic 1 Alain Munafo 2, Mats Karlsson 1
Population Pharmacodynamics of Cladribine Tablets Therapy in Patients with Multiple Sclerosis: Relationship between Magnetic Resonance Imaging and Clinical Outcomes Rada Savic 1 Alain Munafo 2, Mats Karlsson
More informationA hidden Markov model to assess drug-induced sleep fragmentation in the telemetered rat
J Pharmacokinet Pharmacodyn (2011) 38:697 711 DOI 10.1007/s10928-011-9215-3 A hidden Markov model to assess drug-induced sleep fragmentation in the telemetered rat C. Diack O. Ackaert B. A. Ploeger P.
More informationAn imputation-based method to reduce bias in model parameter estimates due to non-random censoring in oncology trials
TCP 2016;24(4):189-193 http://dx.doi.org/10.12793/tcp.2016.24.4.189 An imputation-based method to reduce bias in model parameter estimates due to non-random censoring in oncology trials Dongwoo Chae 1,2
More informationX-Plain Sigmoidoscopy Reference Summary
X-Plain Sigmoidoscopy Reference Summary Introduction Colon diseases are common. A sigmoidoscopy is a test that can help detect colon diseases. If your doctor recommends that you have a sigmoidoscopy, the
More informationAn integrated glucose homeostasis model of glucose, insulin, C-peptide, GLP-1, GIP and glucagon in healthy subjects and patients with type 2 diabetes
An integrated glucose homeostasis model of glucose, insulin, C-peptide, GLP-1, GIP and glucagon in healthy subjects and patients with type 2 diabetes Oskar Alskär, Jonatan Bagger, Rikke Røge, Kanji Komatsu,
More informationMODEL-BASED DOSE INDIVIDUALIZATION APPROACHES USING BIOMARKERS
MODEL-BASED DOSE INDIVIDUALIZATION APPROACHES USING BIOMARKERS CATHERINE M SHERWIN PAGE 27 th Meeting, Montreux, Switzerland 30 th May 2018 Division of Clinical Pharmacology, Pediatrics, School of Medicine
More informationPharmacokinetic Pharmacodynamic Modeling of Severity Levels of Extrapyramidal Side Effects with Markov elements
Citation: CPT: Pharmacometrics & Systems Pharmacology (2012) 1, e1; doi:1038/psp.2012.9 2012 AScpt All rights reserved 2163-8306/12 original article Pharmacokinetic Pharmacodynamic Modeling of Severity
More informationUse of discrete event simulation in health service planning: a luxury or necessity? Ruth Davies
Use of discrete event simulation in health service planning: a luxury or necessity? Ruth Davies Professor of OR and Systems, Warwick Business School University of Warwick ruth.davies@wbs.ac.uk CHEBS FOCUS
More informationA pharmacometric framework for dose individualisation of sunitinib in GIST
A pharmacometric framework for dose individualisation of sunitinib in GIST Maddalena Centanni, Sreenath M. Krishnan, Lena E. Friberg Department of Pharmaceutical Biosciences, Uppsala University, Sweden
More informationAnalysis Strategies for Clinical Trials with Treatment Non-Adherence Bohdana Ratitch, PhD
Analysis Strategies for Clinical Trials with Treatment Non-Adherence Bohdana Ratitch, PhD Acknowledgments: Michael O Kelly, James Roger, Ilya Lipkovich, DIA SWG On Missing Data Copyright 2016 QuintilesIMS.
More informationDRUG EVALUATION IN PEDIATRICS USING K-PD MODELS: PERSPECTIVES
DRUG EVALUATION IN PEDIATRICS USING K-PD MODELS: PERSPECTIVES Michel TOD, PhD Pascal Girard, PhD EA3738, Faculté Médecine Lyon Sud Lyon I University, France Tod / Girard 1 EMEA 14 April 008 USES OF MODELS
More informationMultinomial Markov-chain model of sleep architecture in Phase Advanced Subjects
Multinomial Markov-chain model of sleep architecture in Phase Advanced Subjects C. Steven Ernest II 1,2, Roberto Bizzotto 3, David J DeBrota 2, Lan Ni 2, Cynthia J. Harris 2, Mats O. Karlsson 1, Andrew
More informationModel-based quantification of the relationship between age and anti-migraine therapy
6 Model-based quantification of the relationship between age and anti-migraine therapy HJ Maas, M Danhof, OE Della Pasqua Submitted to BMC. Clin. Pharmacol. Migraine is a neurological disease that affects
More informationPharmacometric Modeling in Rheumatoid Arthritis
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 199 Pharmacometric Modeling in Rheumatoid Arthritis BRIGITTE LACROIX ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2015 ISSN
More informationEstimating and comparing cancer progression risks under varying surveillance protocols: moving beyond the Tower of Babel
Estimating and comparing cancer progression risks under varying surveillance protocols: moving beyond the Tower of Babel Jane Lange March 22, 2017 1 Acknowledgements Many thanks to the multiple project
More informationHow to analyze correlated and longitudinal data?
How to analyze correlated and longitudinal data? Niloofar Ramezani, University of Northern Colorado, Greeley, Colorado ABSTRACT Longitudinal and correlated data are extensively used across disciplines
More informationExposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema
Citation: CPT Pharmacometrics Syst. Pharmacol. (2018) 7, 158 165; VC 2018 ASCPT All rights reserved doi:10.1002/psp4.12271 ARTICLE Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate
More informationModeling disease progression in acute stroke by simultaneously using the NIH Stroke Scale, Scandinavian Stroke Scale and the Barthel Index
Modeling disease progression in acute stroke by simultaneously using the NIH Stroke Scale, Scandinavian Stroke Scale and the Barthel Index Kristin E. Karlsson Justin J. Wilkins, Mats O. Karlsson and E.
More informationph Dependent Drug Delivery System: Review
ph Dependent Drug Delivery System: Review Korake.S.P. SVERI s College of Pharmacy (Poly.), Pandharpur The ph-dependent CTDDS exploit the generally accepted view that ph of the human GIT increases progressively
More informationIs It Insomnia, Is It Hypersomnia, Is It Both? W. Vaughn McCall, MD, MS Wake Forest University Health Sciences
Is It Insomnia, Is It Hypersomnia, Is It Both? W. Vaughn McCall, MD, MS Wake Forest University Health Sciences W. Vaughn McCall, MD, MS Disclosures Research/Grants: Mini-Mitter Co.; National Institute
More informationA Semi-mechanistic Model of Lymphocyte Dynamics in Patients with Multiple Sclerosis Treated with Cladribine Tablets
A Semi-mechanistic Model of Lymphocyte Dynamics in Patients with Multiple Sclerosis Treated with Cladribine Tablets A.L. Quartino (), P. Girard (), M.O. Karlsson (), A. Munafo () () Dept of Pharmaceutical
More informationPopulation Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
Clin Pharmacokinet (2017) 56:1245 1253 DOI 10.1007/s40262-017-0516-6 ORIGINAL RESEARCH ARTICLE Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis Radojka M. Savic 1 Ana M. Novakovic
More informationModel-based optimization of rituximab dosing regimen in follicular non-hodgkin lymphoma
Model-based optimization of rituximab dosing regimen in follicular non-hodgkin lymphoma D. Ternant, E. Hénin, G. Cartron, M. Tod, G. Paintaud, P. Girard Introduction Objectives Introduction Rituximab in
More informationAn integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers
Title: An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers Authors: Hanna E. Silber 1, Nicolas Frey 2 and Mats O. Karlsson 1 Address: 1 Department of
More informationModule Five: Review Questions
1. Which of the following statements IS NOT true? a) Meditation affects brain activity b) All types of meditation lead to same kind of brain activity affection c) The brain travels through different patterns
More informationAN ATYPICAL JOINT MODEL OF PSA AND CTC COUNT KINETICS DURING TREATMENT IN PROSTATE CANCER
AN ATYPICAL JOINT MODEL OF PSA AND CTC COUNT KINETICS DURING TREATMENT IN PROSTATE CANCER Mélanie Wilbaux, Michel Tod, Johann De Bono, David Lorente, Joaquin Mateo, Gilles Freyer, Benoit You, Emilie Hénin
More informationPopulation pharmacokinetics of bedaquiline (TMC207) and its M2 and M3 metabolites with efavirenz demonstrate reduced exposure
Population pharmacokinetics of bedaquiline (TMC207) and its M2 and M3 metabolites with efavirenz demonstrate reduced exposure Elin M Svensson 1 Kelly E Dooley 2, Francesca Aweeka 3, Jeong-Gun Park 4, Mats
More informationModel based longitudinal metaanalysis of FEV1 in COPD trials A tool for efficacy benchmarking
Model based longitudinal metaanalysis of FEV1 in COPD trials A tool for efficacy benchmarking Julia Korell (1), Steven W. Martin (2), Mats O. Karlsson (1), Jakob Ribbing (1,3) (1) Uppsala University, Sweden
More informationMost people need to sleep about 8 hours each night. This is especially true for college students, since the deep sleep that occurs early in the night
Most people need to sleep about 8 hours each night. This is especially true for college students, since the deep sleep that occurs early in the night and the dream sleep that occurs later in the night
More informationPAGE Meeting 2003 Verona, Italy
PAGE Meeting 2003 Verona, Italy Population pharmacokinetics/-dynamics of the direct thrombin inhibitor dabigatran in patients undergoing hip replacement surgery J. Stangier 1, K.H. Liesenfeld 1, C. Tillmann
More informationAsymmetric Injury in Carpal Tunnel Syndrome. C. J. Zheng, MD, PhD. Department of Occupational and Environmental Medicine.
Asymmetric Injury in Carpal Tunnel Syndrome C. J. Zheng, MD, PhD Department of Occupational and Environmental Medicine Regions Hospital University of Minnesota Saint Paul, Minnesota Tel: 65-54-3443 Pager:
More informationSleep Patients with Daytime SOREMs Exhibit More Daytime Sleepiness but Similar Fatigue
Sleep Patients with Daytime SOREMs Exhibit More Daytime Sleepiness but Similar Fatigue Alison L. Gibbs, PhD, PStat March 10, 2011 Summary: This report considers whether sleep clinic patients with daytime
More informationGENERALIZED ESTIMATING EQUATIONS FOR LONGITUDINAL DATA. Anti-Epileptic Drug Trial Timeline. Exploratory Data Analysis. Exploratory Data Analysis
GENERALIZED ESTIMATING EQUATIONS FOR LONGITUDINAL DATA 1 Example: Clinical Trial of an Anti-Epileptic Drug 59 epileptic patients randomized to progabide or placebo (Leppik et al., 1987) (Described in Fitzmaurice
More informationTHE ANALYSES TO DETERMINE THE RELATIONSHIP BETWEEN SLEEPING PROBLEMS AND THE HEALTH OUTCOMES OF THE ELDER PEOPLE
THE ANALYSES TO DETERMINE THE RELATIONSHIP BETWEEN SLEEPING PROBLEMS AND THE HEALTH OUTCOMES OF THE ELDER PEOPLE A study submitted in partial fulfillment of the requirements for the degree of Master of
More informationImproved Utilization of ADAS-Cog Assessment Data Through Item Response Theory Based Pharmacometric Modeling
Pharm Res (2014) 31:2152 2165 DOI 10.1007/s11095-014-1315-5 RESEARCH PAPER Improved Utilization of ADAS-Cog Assessment Data Through Item Response Theory Based Pharmacometric Modeling Sebastian Ueckert
More informationA model-based analysis to describe bedaquiline s exposure-response relationship and predict the impact of drugdrug interactions
9th International Workshop on Clinical Pharmacology of TB Drugs 24 October 2016, Liverpool, UK A model-based analysis to describe bedaquiline s exposure-response relationship and predict the impact of
More informationFlexible Sigmoidoscopy
Flexible Sigmoidoscopy National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is flexible sigmoidoscopy? Flexible sigmoidoscopy
More informationSleep and Ageing. Siobhan Banks PhD. Body and Brain at Work, Centre for Sleep Research University of South Australia
Sleep and Ageing Siobhan Banks PhD Body and Brain at Work, Centre for Sleep Research University of South Australia Health and Active Ageing, 22 nd September 2015 Sleep and Aging How does sleep change as
More informationmodels proposed by Richardson et al. (2010), Widén et al. (2010), and Tanimoto et al. (2008). These models employ time use data (TUD), which show how
Behavior Model of Occupants in Home based on Japanese National Time Use Survey Yohei Yamaguchi 1,2*, Yoshiyuki Shimoda 1,2 1 Graduate School of Engineering Osaka University, S4 Building, 2-1 Yamadaoka,
More informationPOPULATION PHARMACOKINETICS RAYMOND MILLER, D.Sc. Daiichi Sankyo Pharma Development
POPULATION PHARMACOKINETICS RAYMOND MILLER, D.Sc. Daiichi Sankyo Pharma Development Definition Population Pharmacokinetics Advantages/Disadvantages Objectives of Population Analyses Impact in Drug Development
More informationPharmacokinetic Modeling & Simulation in Discovery and non-clinical Development
Pharmacokinetic Modeling & Simulation in Discovery and non-clinical Development Where do we stand? Disclaimer I am not a bioinformatician, mathematician or biomedical engineer. I am a simple minded pharmacist,
More informationMidterm Exam ANSWERS Categorical Data Analysis, CHL5407H
Midterm Exam ANSWERS Categorical Data Analysis, CHL5407H 1. Data from a survey of women s attitudes towards mammography are provided in Table 1. Women were classified by their experience with mammography
More informationSleep 101 Learning More About Recovery
Sleep 101 Learning More About Recovery Alan Tyson PT, ATC Sleep is a dynamic process. The average healthy adult will experience 3-5 cycles of sleep in a night. Within those cycles, there are 4 distinct
More informationCase Study in Placebo Modeling and Its Effect on Drug Development
Case Study in Placebo Modeling and Its Effect on Drug Development Modeling and Simulation Strategy for Phase 3 Dose Selection of Dasotraline in Patients With Attention-Deficit/Hyperactivity Disorder Julie
More informationModeling Dynamic Gastrointestinal Fluid Transit as a Basis for Dissolution and Absorption
Modeling Dynamic Gastrointestinal Fluid Transit as a Basis for Dissolution and Absorption Duxin Sun, Ph.D. William I. Higuchi Collegiate Professor Department of Pharmaceutical Sciences Pharmacokinetics
More informationUniversity of Groningen. Translational PKPD modeling in schizophrenia Pilla Reddy, Venkatesh
University of Groningen Translational PKPD modeling in schizophrenia Pilla Reddy, Venkatesh IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationDichotomizing partial compliance and increased participant burden in factorial designs: the performance of four noncompliance methods
Merrill and McClure Trials (2015) 16:523 DOI 1186/s13063-015-1044-z TRIALS RESEARCH Open Access Dichotomizing partial compliance and increased participant burden in factorial designs: the performance of
More informationPKPD Modeling of VEGF, svegfr-2, svegfr-3, and skit as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST
Original Article Citation: CPT: Pharmacometrics & Systems Pharmacology (213) 2, e84; doi:1.138/psp.213.61 213 ASCPT All rights reserved 2163-836/12 PKPD Modeling of VEGF, svegfr-2, svegfr-3, and skit as
More informationAnalysis of variance and regression. Other types of regression models
Analysis of variance and regression ther types of regression models ther types of regression models ounts: Poisson models rdinal data: Proportional odds models Survival analysis (censored, time-to-event
More informationResearch Article. Philippe B. Pierrillas, 1,3,5 Michel Tod, 1,2 Magali Amiel, 3 Marylore Chenel, 4 and Emilie Henin 1
The AAPS Journal, Vol. 18, No. 2, March 2016 ( # 2016) DOI: 10.1208/s12248-015-9862-1 Research Article Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: a Novel
More informationUniversity of Groningen. Translational PKPD modeling in schizophrenia Pilla Reddy, Venkatesh
University of Groningen Translational PKPD modeling in schizophrenia Pilla Reddy, Venkatesh IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationPK-PD modelling to support go/no go decisions for a novel gp120 inhibitor
PK-PD modelling to support go/no go decisions for a novel gp120 inhibitor Phylinda LS Chan Pharmacometrics, Pfizer, UK EMA-EFPIA Modelling and Simulation Workshop BOS1 Pharmacometrics Global Clinical Pharmacology
More informationWhat is sleep? A state of altered consciousness, characterized by certain patterns of brain activity and inactivity.
Sleep and Dreams What is sleep? A state of altered consciousness, characterized by certain patterns of brain activity and inactivity. A state we do not know we are in until we leave it. Characterized by
More informationFacts about Sleep. Circadian rhythms are important in determining human sleep patterns/ sleep-waking cycle
Sleep Sleep is described as a state of unconsciousness or partial consciousness from which a person can be roused by stimulation Period of rest and recovery People spend about a third of their lives sleeping
More informationMultiple equilibria in social interaction models: estimating a model of adolescent smoking behavior.
Multiple equilibria in social interaction models: estimating a model of adolescent smoking behavior. Andrea Moro, Vanderbilt University (with Alberto Bisin and Giorgio Topa) Michigan State University,
More informationMODULE 08: SLEEP, DREAMS, AND BODY RHYTHMS CONSCIOUSNESS
MODULE 08: SLEEP, DREAMS, AND BODY RHYTHMS CONSCIOUSNESS CONSCIOUSNESS Awareness of yourself and your environment. CIRCADIAN RHYTHMS Biological rhythms (for example, of temperature and wakefulness) that
More informationDr. Nele Plock. Dr. N. Plock, March 11, 2008, American Conference on Pharmacometrics
Parallel PKPD modeling of an endogenous agonist (A) and exogenous antagonist (B) based on research PKPD data to predict an effective first-in-man dose of B A combination of physiologically based PK and
More informationCLINICAL TRIAL SIMULATION & ANALYSIS
1 CLINICAL TRIAL SIMULATION & ANALYSIS Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand NHG Holford, 217, all rights reserved. 2 SIMULATION Visualise the expected
More informationWebinar Q&A Report Noninvasive, Automated Measurement of Sleep, Wake and Breathing in Rodents
Webinar Q&A Report Noninvasive, Automated Measurement of Sleep, Wake and Breathing in Rodents Q: How does the PiezoSleep system distinguish between inactivity (quiet wake) vs. sleep? B. O Hara: The piezo
More informationBackground Comparative effectiveness of nivolumab
NCPE report on the cost effectiveness of nivolumab (Opdivo ) for the treatment of locally advanced or metastatic squamous non-small cell lung cancer after prior chemotherapy in adults. The NCPE has issued
More informationEPI 200C Final, June 4 th, 2009 This exam includes 24 questions.
Greenland/Arah, Epi 200C Sp 2000 1 of 6 EPI 200C Final, June 4 th, 2009 This exam includes 24 questions. INSTRUCTIONS: Write all answers on the answer sheets supplied; PRINT YOUR NAME and STUDENT ID NUMBER
More informationOVERVIEW. Somnuva: a new way to sleep
PRESENTATION 2 2 OVERVIEW Independent research shows that at least 1 in 3 adults suffer from sleeplessness at some stage in their life. Poor sleep impacts both health and work life; Rand Europe recently
More informationA Mechanism-Based PK/PD Model Predicts the Time-Course of Hematological responses for Epoetin beta
A Mechanism-Based PK/PD Model Predicts the Time-Course of Hematological responses for Epoetin beta N. Hayashi, K. P. Zuideveld, P. Jordan & R. Gieschke Modeling & Simulation Group & Biometrics, F. Hoffmann-La
More informationColon Cancer Surgery
Colon Cancer Surgery Introduction Colon cancer is a life-threatening condition that affects thousands of people. Doctors usually recommend surgery for the removal of colon cancer. If your doctor recommends
More informationPrediction of Malignant and Benign Tumor using Machine Learning
Prediction of Malignant and Benign Tumor using Machine Learning Ashish Shah Department of Computer Science and Engineering Manipal Institute of Technology, Manipal University, Manipal, Karnataka, India
More informationSLEEP STUDY. Nighttime. 1. How many hours of sleep are you now getting in a typical night?
SLEEP STUDY Patient Name: Date of Birth: Date of Study: This questionnaire involves a broad range of sleep and sleep-related behaviors. Your answers enable us to develop a clearer picture of your sleep/wake
More informationUtilizing the items from the MDS-UPDRS score to increase drug effect detection power in de novo idiopathic Parkinson's disease patients
Utilizing the items from the MDS-UPDRS score to increase drug effect detection power in de novo idiopathic Parkinson's disease patients Simon Buatois 1,3, Sylvie Retout 1, Nicolas Frey 1, Sebastian Ueckert
More informationSleep problems 4/10/2014. Normal sleep (lots of variability at all ages) 2 phases of sleep. Quantity. Quality REM. Non-REM.
Sleep problems Normal sleep (lots of variability at all ages) Quantity Newborns: 16-20 hrs/day 1-yr olds: 12 hrs/day 6-12 yr olds: 10-11 hrs/day Quality Newborns: distributed between day and night 3-months:
More informationAltered GI absorption in special populations: An industry perspective
Altered GI absorption in special populations: An industry perspective Cordula Stillhart and Neil J. Parrott F. Hoffmann La Roche Ltd, Basel (CH) UNGAP WG meeting, Leuven (B) 8 March 2018 Current challenges
More informationA Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients
Citation: CPT Pharmacometrics Syst. Pharmacol. (217) 6, 373 382; VC 217 ASCPT All rights reserved doi:1.2/psp4.12193 ORIGINAL ARTICLE A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety
More informationMedications that are not FDA approved for children will be discussed. NAPNAP National Conference 2018
Medications that are not FDA approved for children will be discussed NAPNAP National Conference 2018 (Honaker & Meltzer, 2016; Keyes, Maslowsky, Hamilton & Schulenberg, 2015) Chronically disrupted sleep
More informationKey FM scientific principles
Key FM scientific principles Philippa Gander Research Professor, Director Fatigue Management Approaches Symposium 5-6 April 2016, Montréal, Canada Fatigue a physiological state of reduced mental or physical
More informationA population pharmacokinetic model for rifampicin auto induction
A population pharmacokinetic model for rifampicin auto induction Paolo Denti 1, Wynand Smythe 1, Ulrika SH Simonsson 2, Roxana Rustomjee 3, Philip Onyebujoh 4, Peter Smith 1, Helen McIlleron 1 1 Division
More informationWhat to do with missing data in clinical registry analysis?
Melbourne 2011; Registry Special Interest Group What to do with missing data in clinical registry analysis? Rory Wolfe Acknowledgements: James Carpenter, Gerard O Reilly Department of Epidemiology & Preventive
More informationLevel 2: Critical Appraisal of Research Evidence
Evidence-Informed Practice Workshop Series Level 2: Critical Appraisal of Research Evidence Outline Introduction to Critical Appraisal Break Critical Appraisal - Intervention Study Independent review and
More informationA Comparison of Methods of Estimating Subscale Scores for Mixed-Format Tests
A Comparison of Methods of Estimating Subscale Scores for Mixed-Format Tests David Shin Pearson Educational Measurement May 007 rr0701 Using assessment and research to promote learning Pearson Educational
More informationDiscontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database
open access Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database Yana Vinogradova, 1 Carol Coupland, 1 Peter Brindle, 2,3 Julia Hippisley-Cox
More informationPhysiology Unit 2 CONSCIOUSNESS, THE BRAIN AND BEHAVIOR
Physiology Unit 2 CONSCIOUSNESS, THE BRAIN AND BEHAVIOR In Physiology Today What the Brain Does The nervous system determines states of consciousness and produces complex behaviors Any given neuron may
More informationImplementing receptor theory in PK-PD modeling
Drug in Biophase Drug Receptor Interaction Transduction EFFECT Implementing receptor theory in PK-PD modeling Meindert Danhof & Bart Ploeger PAGE, Marseille, 19 June 2008 Mechanism-based PK-PD modeling
More informationLec 02: Estimation & Hypothesis Testing in Animal Ecology
Lec 02: Estimation & Hypothesis Testing in Animal Ecology Parameter Estimation from Samples Samples We typically observe systems incompletely, i.e., we sample according to a designed protocol. We then
More informationLecture #4: Overabundance Analysis and Class Discovery
236632 Topics in Microarray Data nalysis Winter 2004-5 November 15, 2004 Lecture #4: Overabundance nalysis and Class Discovery Lecturer: Doron Lipson Scribes: Itai Sharon & Tomer Shiran 1 Differentially
More informationUse of PBPK in simulating drug concentrations in pediatric populations: Case studies of Midazolam and Gabapentin
Use of PBPK in simulating drug concentrations in pediatric populations: Case studies of Midazolam and Gabapentin WORKSHOP ON MODELLING IN PAEDIATRIC MEDICINES April 2008 Viera Lukacova, Ph.D. Walter Woltosz,
More informationObjectives. 0 Identify medicines which increase the risk of falls and secondary injury on the farm/ranch.
Objectives 0 Identify medicines which increase the risk of falls and secondary injury on the farm/ranch. 0 Examine the impact of a medication assessment service on Missouri AgrAbility clients confidence
More informationPhysiology Unit 2 CONSCIOUSNESS, THE BRAIN AND BEHAVIOR
Physiology Unit 2 CONSCIOUSNESS, THE BRAIN AND BEHAVIOR What the Brain Does The nervous system determines states of consciousness and produces complex behaviors Any given neuron may have as many as 200,000
More informationarxiv: v1 [cs.lg] 6 Oct 2016
Combining Generative and Discriminative Neural Networks for Sleep Stages Classification Endang Purnama Giri 1,2, Mohamad Ivan Fanany 1, Aniati Murni Arymurthy 1, arxiv:1610.01741v1 [cs.lg] 6 Oct 2016 1
More informationHuman Anatomy rectum
rectum The colon is also called the large intestine. The ileum (last part of the small intestine) connects to the cecum (first part of the colon) in the lower right abdomen. The rest of the colon is divided
More informationMulti-state survival analysis in Stata
Multi-state survival analysis in Stata Michael J. Crowther Biostatistics Research Group Department of Health Sciences University of Leicester, UK michael.crowther@le.ac.uk Italian Stata Users Group Meeting
More informationPOPULATION PHARMACOKINETICS
POPULATION PHARMACOKINETICS Raymond Miller, D.Sc. Daiichi Sankyo Pharma Development 1 Population Pharmacokinetics Definition Advantages/Disadvantages Objectives of Population Analyses Impact in Drug Development
More informationSLEEP DISTURBANCE ABOUT SLEEP DISTURBANCE INTRODUCTION TO ASSESSMENT OPTIONS. 6/27/2018 PROMIS Sleep Disturbance Page 1
SLEEP DISTURBANCE A brief guide to the PROMIS Sleep Disturbance instruments: ADULT PROMIS Item Bank v1.0 Sleep Disturbance PROMIS Short Form v1.0 Sleep Disturbance 4a PROMIS Short Form v1.0 Sleep Disturbance
More informationModel-Based Approach to Predict Adherence to Protocol During Antiobesity Trials
Modeling and Simulation Model-Based Approach to Predict Adherence to Protocol During Antiobesity Trials The Journal of Clinical Pharmacology 2018, 58(2) 240 253 C 2017, The Authors. The Journal of Clinical
More informationSimulation of Membrane and Cell Culture Permeability and Transport. Michael B. Bolger and Viera Lukacova Simulations Plus, Inc.
Simulation of Membrane and Cell Culture Permeability and Transport Michael B. Bolger and Viera Lukacova Simulations Plus, Inc. utline Models of microscopic membrane kinetics Calculation of membrane entry
More information